Insights

India’s pharmaceutical industry continues to invest heavily in expansion. Whether driven by increasing demand, entry into regulated markets, diversification into biologics, or the addition of new manufacturing lines, expansion projects have become a strategic priority

Qualification has always been one of the most documentation-intensive phases in pharmaceutical engineering – but today’s projects demand a faster, smarter, and more connected approach. For decades, qualification activities such as Factory Acceptance Testing (FAT),

In biopharmaceuticals, quality is often discussed in the context of manufacturing. However, long before a product reaches the production floor, critical decisions have already been made – decisions that define how consistently, efficiently, and reliably

India’s Union Budget 2026 and the national biopharma initiatives are accelerating investment across advanced therapeutics, vaccines, and biologics manufacturing. Programs such as the government’s Biopharma Mission, aimed at strengthening translational research and domestic manufacturing capabilities,

What to look for – and how to avoid common pitfalls in greenfield and brownfield facilities Whether you are building a new biopharma facility from the ground up or upgrading an existing one, the choice

India’s biopharmaceutical industry is entering a new phase of expansion. Beyond its established leadership in vaccines and biosimilars, the country is now investing across advanced modalities, including monoclonal antibodies, cell and gene therapies, plasma products,

Sustainability is no longer a side conversation in the pharmaceutical industry — it is becoming a core design principle. As global demand for medicines rises and manufacturing scales up, the environmental footprint of pharma production

India’s pharmaceutical manufacturing sector is experiencing rapid growth, reinforcing its position as the “pharmacy of the world.” According to the EY-Parthenon–OPPI report, pharma exports reached $27.85 billion in FY 2023–24, nearing the $30 billion mark.

The global fermenters market reached $1.80 billion in 2025 and is projected to reach $2.63 billion by 2032 at a 5.60% CAGR, driven by rising biopharma demand for vaccines, biosimilars, and recombinant proteins. In the

In the highly regulated and complex pharma and biotech sectors, fragmented engineering processes often lead to costly delays, compliance issues, and inefficient facilities that hinder production scale-up. Project managers, production heads, and CEOs need a

After the founders closed their seed round for a biotech startup, it felt like the hardest part was behind them. The upstream platform for a new class of recombinant proteins had worked beautifully in the

A simulation-first approach is quickly becoming non‑negotiable in biopharma facilities – both greenfield and brownfield projects. It is one of the few levers that can simultaneously de‑risk capex, compress timelines and stabilise operations over a